AzTrials
AzTrials

Blood DiseaseNCT00005438

Neuropsychological Studies of Children With Sickle Cell

An observational study of Blood Disease and Anemia, Sickle Cell, run by National Heart, Lung, and Blood Institute (NHLBI).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities. Read more about this study

Who is it for?
Ages Up to 100 years, men only
How many people
Not given
Where
No sites listed yet
Study dates
Feb 1993to Jan 1998
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 100 years
  • Men only
  • No healthy volunteers
  • Child, Adult, Older adult

No eligibility criteria

About this study

To identify those factors that contributed to cognitive deficiencies in children with sickle cell disease (SCD) who had not demonstrated any overt or clinically apparent neurological abnormalities.

Read the detailed description

BACKGROUND:

Although there has been evidence for a relationship between sickle cell disease and pathology of the central nervous system since 1923, there has been a tendency in the psychosocial literature to attribute any decreased cognitive performance in children with sickle cell disease to illness-related or demographic factors (e.g., school absenteeism, socioeconomic status) rather than to the disease process of SCD (e.g., chronic microvascular insults to the central nervous system). Cerebral infarction is the most common neurological complication that occurs in children with SCD, but clinically it presents itself in only five to ten percent of children with this chronic illness. The majority of children with SCD are also at high risk of demonstrating learning deficits and poor school performance. Studies suggest that a significant number of children with SCD who do not display any overt symptomatology of neurologic disease often exhibit decreased academic performance in comparison to healthy matched peers. Given the pathophysiology of SCD, it is reasonable to hypothesize that the insidious onset of impaired cognitive functioning is the result of multiple microinfarcts, small hemorrhages, and progressive vascular disease. Therefore, the disease process of SCD could be a primary contributing factor to long-term decreased cognitive performance often demonstrated by the adult SCD population. It is thus critical to examine young children with SCD who do not exhibit gross manifestations of neurological insult in order to determine the cause of these cognitive deficits.

DESIGN NARRATIVE:

A total of 60 infants and toddlers with SCD and 60 matched normally-developing peers between the ages of birth and three years served as subjects in a five-year longitudinal design in order to permit between-group comparisons. Subjects were assessed at regularly scheduled intervals with a variety of developmental (e.g., Bayley), cognitive (e.g., Stanford-Binet), neuropsychological (e.g., Purdue Pegboard), family functioning, and physiological indices in order to delineate those factors in the SCD group that were associated with decreased cognitive and academic performance. A unique and important feature of this research was the inclusion of magnetic resonance imaging technology. These techniques made it possible to study in a comprehensive and componential manner the neuroanatomical effects of SCD instead of relying on any single instrument or assessment to document this phenomenon. Goals of this study included the identification of: (a) specific areas of learning deficiencies in children with SCD; (b) the period in which these deficiencies began to occur; and (c) the relationship between types of learning deficits and various outcome measures. In sum, this study helped to determine how these factors interacted and changed over time as the child with SCD matured, the disease fluctuated, and the family and/or the environmental context changed in relation to cognitive development.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Medical subject headings
Hematologic Diseases, Anemia, Sickle Cell, Neurologic Manifestations

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2000 (estimated)
  2. Study startFeb 1993
  3. Study completionJan 1998

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
IDs, dates and publications
ClinicalTrials.gov ID
NCT00005438
Sponsor's protocol ID
4366
Other IDs
R29HL047872
Status last verified
Nov 2001
First submitted
25 May 2000
Last updated
13 May 2016
Results posted
No

Questions about this trial

What is this clinical trial studying?

An observational study of Blood Disease and Anemia, Sickle Cell, run by National Heart, Lung, and Blood Institute (NHLBI).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 May 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in